بررسی اثر بخشی درمان توام کرم Pimecrolimus یک درصد و کرم Mometazone در مقایسه با هر کدام به تنهایی در درمان ویتیلیگوی کودکان

Background and purpose: Vitiligo is a common acquired pigmentation disorder. There are various therapeutic options for the treatment of vitiligo which bare some limitations due to their side effects. Recently topical immunomodulators (TIMS) such as topical Pimecrolimus have been used for the treatment of vitiligo in children as safe and efficient therapeutic options. This study compared the efficacy of the combination therapy of Pimecrolimus 1% cream and Mometasone cream with either agent alone in the treatment of childhood vitiligo. Materials and methods: In a nonrandomized double blind interventional study, 50 patients were enrolled. In each patient three lesions was selected. Topical Pimecrolimus cream 1% was applied to the first lesion twice daily, topical Mometasone furoat 0.1% ointment was applied for the second lesion every night, and Pimecrolimus cream 1% and topical Mometasone ointment 0.1% were applied to the third lesion twice/daily for the first five days. Topical Mometasone furoat 0.1% ointment was used at nights for the rest of the days of the week. All three treatments were administered simultaneously over three months. The data was analyzed using SPSS V.20. Results: Forty patients completed the study period whose mean age was 10.6 years and 46% were male. Significant decreasing trend was seen in the lesions size over time (P< 0.0001). However, this decreasing trend was not statistically significant among the three treatment groups at the end of the study (P= 0.5). Conclusion: In this study combination therapy had no any advantage to either Pimecrolimus or Mometasone. However, due to the limited number of patients in this study, further studies with large sample sizes are needed to evaluate the efficacy of this type of combination therapy and other combination therapies. (Clinical Trials Registry Number: ACTRN12611001165976)